{"entity":{"id":"nct03899155","kind":"trial","name":"Pan Tumor Rollover Study","aka":[],"tldr":"A phase 2 trial of Nivolumab, Ipilimumab, Cabozantinib, Trametinib, Capecitabine and Bevacizumab in advanced solid tumours, run by Bristol-Myers Squibb, now recruiting.","summary":"Pan Tumor Rollover Study is a phase 2 interventional study registered as NCT03899155 by Bristol-Myers Squibb, with 1500 participants planned, started 2019-08-09 and due to reach its primary completion in 2029-08-25. Interventions recorded: Nivolumab, Ipilimumab, Cabozantinib, Trametinib, Relatlimab and Nivolumab + Relatlimab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03899155","url":"https://clinicaltrials.gov/study/NCT03899155"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["nivolumab","ipilimumab","cabozantinib","trametinib","capecitabine","bevacizumab"],"companies":["bms","exelixis","novartis","clovis-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03899155","phase":"2","setting":"Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies","sponsor":"Bristol-Myers Squibb","participation":[{"nct":"NCT03899155","source":"https://clinicaltrials.gov/study/NCT03899155","fetchedAt":"2026-10-07T16:53:10.842Z","studySha256":"359fd29e715b00adf75b31b1d080c0e2d170c09d0e5f305b497deb9fd348626b","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-23","leadSponsor":"Bristol-Myers Squibb","collaboratorCount":4,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":1500,"enrolmentType":"ESTIMATED","siteCount":399,"recruitingSiteCount":108,"countries":["Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Czechia","Denmark","Finland","France","Germany","Greece","Hong Kong","Hungary","Ireland","Israel","Italy","Japan","Mexico","Netherlands","New Zealand","Norway","Peru","Poland","Portugal","Puerto Rico","Romania","Russia","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2019-08-09","startedType":"actual","enrolled":1500,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03899155/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"cabozantinib","kind":"drug","name":"Cabozantinib","route":"/drugs/cabozantinib/"},{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"trametinib","kind":"drug","name":"Trametinib","route":"/drugs/trametinib/"}],"company":[{"id":"advanced-accelerator-applications","kind":"company","name":"Advanced Accelerator Applications (Novartis)","route":"/companies/advanced-accelerator-applications/"},{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"},{"id":"clovis-oncology","kind":"company","name":"Clovis Oncology","route":"/companies/clovis-oncology/"},{"id":"exelixis","kind":"company","name":"Exelixis","route":"/companies/exelixis/"},{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}]}}